Physician profile
Troy A Jensen
NPI 1316561608
$2,394.47
in general payments reported to CMS, 2019-2025
21 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.31 · 2022: $146 · 2023: $453 · 2024: $1,110 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $364.08 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $327.12 | 2024-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $267.84 | 2022-2024 | Mounjaro |
| Abbott Laboratories | $236.67 | 2024-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.28 | 2023-2024 | Jardiance |
| Phadia US INC. | $140.73 | 2023-2025 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $124.99 | 2025 | Zoryve |
| Inspire Medical Systems, INC. | $114.24 | 2024 | Inspire |
| Corcept Therapeutics | $90.75 | 2025 | Korlym |
| Heartflow, INC. | $78.45 | 2025 | |
| Abbvie INC. | $72.24 | 2021-2024 | |
| Novo Nordisk INC | $71.49 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $55.21 | 2022-2025 | |
| Exact Sciences Corporation | $45.22 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $40.40 | 2025 | Vyepti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $39.59 | 2024 | Gvoke Hypopen |
| Hologic Sales and Service, LLC | $24.77 | 2021 | |
| Ucb, INC. | $21.32 | 2025 | Briviact |
| Regeneron Healthcare Solutions, INC. | $19.34 | 2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.78 | 2025 | Xifaxan |
| Esperion Therapeutics, INC. | $13.96 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.